Addex to Present at the Swiss Biotech Day 2024
April 19, 2024 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that...
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
April 18, 2024 01:00 ET
|
Addex Therapeutics
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical...
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
April 11, 2024 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that...
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
April 03, 2024 01:00 ET
|
Addex Therapeutics
Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and...
Addex to Present at the Bio-Europe Spring 2024 Conference
March 14, 2024 02:00 ET
|
Addex Therapeutics
Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today...
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
January 31, 2024 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 31, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based...
Addex to Present at the Swiss Equities Baader Conference
January 09, 2024 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
Addex to Present at Biotech Showcase™ 2024
January 05, 2024 01:30 ET
|
Addex Therapeutics
CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
December 20, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 20, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Creates Treasury Shares
December 14, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 14, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...